Anesiva is a late-stage biopharmaceutical company that has been dedicated to becoming the leader in the development and commercialization of novel pharmaceutical products for pain management since its founding in 1999. Based in the United States, the company has garnered investor attention, with its most recent $2.00M post-IPO debt investment occurring on 04 June 2009.
Given the increasing demand for effective pain management solutions, Anesiva’s focus on developing innovative pharmaceutical products positions it well within the biotechnology and health care industries. Moreover, the company’s ability to attract post-IPO debt investment reflects investor confidence in its strategic direction and growth potential in the market.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | $2.00M | - | 04 Jun 2009 | |
| Post-IPO Equity | $3.00M | - | 30 Jan 2009 | |
| Post-IPO Equity | $25.00M | 1 |
|
18 Dec 2007 |
| Series D | $20.00M | 3 |
|
23 Oct 2003 |
| Series C | $50.37M | 6 |
|
23 Jul 2002 |
No recent news or press coverage available for Anesiva.
We care about your data, and we'd love to use cookies make your experience better.